New Drug Approval: FDA’s Consideration of Evidence from Certain Clinical Trials

Home > Diane Publishing Books >

Our Price: $30.00

By Marcia Crosse
Year: 2010
Pages: 38
Binding Paperback
ISBN 9781437938586

Product Code: 1437938582

Description

Before approving a new drug, the FDA assesses a drug's effectiveness. To do so, it examines info. contained in a new drug application (NDA), including data from clinical trials in humans. Several types of trials may be used to gather this evidence. Non-inferiority trials aim to demonstrate that the difference between the effectiveness of a new drug and an active control is small enough to show that the new drug is also effective. FDA has issued guidance on these trials. This report: (1) identifies NDAs for new molecular entities -- potentially innovative new drugs not FDA-approved in any form -- that included evidence from non-inferiority trials; (2) examines the characteristics of these trials; and (3) describes FDA's guidance on these trials. Illustrations.

Share your knowledge of this product with other customers... Be the first to write a review